All In Biotech

Drug Trial Radar · NCT00002599

Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma

MYELOMA VII MEDICAL RESEARCH COUNCIL WORKING PARTY ON LEUKEMIA IN ADULTS: MYELOMATOSIS THERAPY TRIAL

Last checked: Nov 20, 2026Latest source record: Dec 19, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 750 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

750

Planned (sponsor's estimate)

Start

Sep 1994

Primary completion

Not stated

Sponsor

Lead sponsor
Medical Research CouncilGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
May 21, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Primary purpose
Treatment
Who can join
All sexes, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining bone marrow or peripheral stem cell transplantation with chemotherapy may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Interferon alfa may interfere with the growth of cancer cells. It is not yet known whether a more intensive chemotherapy regimen plus stem cell or bone marrow transplant is more effective than standard chemotherapy in treating patients with myeloma. PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of combination chemotherapy plus interferon alfa with or without high dose melphalan or bone marrow or peripheral stem cell transplantation in treating patients with previously untreated myeloma.

Conditions

  • Multiple Myeloma and Plasma Cell Neoplasm

Interventions

  • filgrastimBiological

  • recombinant interferon alfaBiological

  • sargramostimBiological

  • carmustineDrug

  • cyclophosphamideDrug

  • doxorubicin hydrochlorideDrug

  • melphalanDrug

  • methylprednisoloneDrug

  • prednisoneDrug

  • vincristine sulfateDrug

  • low-LET cobalt-60 gamma ray therapyRadiation

  • low-LET photon therapyRadiation

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Leeds Teaching Hospital Trust

    Leeds, England, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.